46,715 results match your criteria Blood[Journal]


Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma.

Blood 2019 Feb 15. Epub 2019 Feb 15.

Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, United States

Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare subtype of lymphoma that, like other Hodgkin lymphomas, has historically been treated aggressively. However, in most cases, NLPHL has an indolent course, which raises the question to what extent these patients require aggressive upfront treatment. We describe the management and outcomes of consecutive NLPHL patients diagnosed at Memorial Sloan Kettering Cancer Center (MSK), with a focus on evaluating active surveillance. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2018-10-877761DOI Listing
February 2019

Characterization and treatment of congenital thrombotic thrombocytopenic purpura.

Blood 2019 Feb 15. Epub 2019 Feb 15.

Department of Haematology, University College London Hospital, London, United Kingdom.

Congenital Thrombotic Thrombocytopenic Purpura (cTTP) is an ultra rare thrombomicroangiopathy caused by an inherited deficiency of ADAMTS13. There is limited data on the genotype-phenotype correlation and no consensus on treatment. We reviewed the largest cohort of cTTP cases, diagnosed in the UK, over the past 15 years. Read More

View Article

Download full-text PDF

Source
http://www.bloodjournal.org/lookup/doi/10.1182/blood-2018-11
Publisher Site
http://dx.doi.org/10.1182/blood-2018-11-884700DOI Listing
February 2019
1 Read

Increased galactose expression and enhanced clearance in patients with Low von Willebrand factor.

Blood 2019 Feb 15. Epub 2019 Feb 15.

Haemostasis Research Group, Department of Molecular and Cellular Therapeutics, Irish Centre for Vascular Biology, Royal College of Surgeons in Ireland, Dublin, Ireland.

Glycan determinants on von Willebrand factor (VWF) play critical roles in regulating its susceptibility to proteolysis and clearance. Abnormal glycosylation has been shown to cause VWD in a number of different mouse models. However, due to the significant technical challenges associated with accurate assessment of VWF glycan composition, the importance of carbohydrates in human VWD pathogenesis remains largely unexplored. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2018-09-874636DOI Listing
February 2019

Intraocular toxoplasmosis mimicking vitreous lymphoma.

Blood 2019 Feb;133(7):767

University of California at Los Angeles.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2018-10-883124DOI Listing
February 2019

Hepatocyte tPA: where have you been hiding?

Authors:
Steven L Gonias

Blood 2019 Feb;133(7):631-632

University of California San Diego.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2018-12-891515DOI Listing
February 2019

More than one pathway: novel treatment for ITP.

Blood 2019 Feb;133(7):629-630

The Children's Hospital of Philadelphia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2018-12-892778DOI Listing
February 2019

Yet another susceptibility variant for ALL: what's next?

Blood 2019 Feb;133(7):628-629

University of Copenhagen.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2018-12-891564DOI Listing
February 2019

Off-target effects of carfilzomib that cause cardiotoxicity.

Authors:
Jan S Moreb

Blood 2019 Feb;133(7):626-628

University of Florida.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2018-12-889758DOI Listing
February 2019

IDH2 inhibition: another piece to the puzzle.

Authors:
Lars Bullinger

Blood 2019 Feb;133(7):625-626

Charité University Medicine.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2018-12-891481DOI Listing
February 2019

Megakaryocytes from fat: a new recipe for platelets.

Blood 2019 Feb;133(7):623-625

University of Pavia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2018-12-889766DOI Listing
February 2019

Myeloma bone disease: from biology findings to treatment approaches.

Blood 2019 Feb 13. Epub 2019 Feb 13.

Department of Clinical Therapeutics, Alexandra General Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.

Bone disease is a cardinal complication of multiple myeloma that affects quality of life and survival. Osteocytes have emerged as key players in the development of myeloma-related bone disease. Along with other factors they participate in increased osteoclast activity, decreased osteoblast function and immunosuppressed marrow microenvironment that deregulate bone turnover and result in bone loss and skeletal-related events. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2018-11-852459DOI Listing
February 2019
1 Read

Comprehensive clinical-molecular transplant scoring system for myelofibrosis undergoing stem cell transplantation.

Blood 2019 Feb 13. Epub 2019 Feb 13.

Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany;

Allogeneic hematopoietic stem cell transplantation is curative in myelofibrosis and current prognostic scoring systems aim to select patients for transplantation. Here, we aimed to develop a prognostic score to determine prognosis after transplantation itself using clinical, molecular and transplant-specific information of a total of 361 myelofibrosis patients. Of these, 205 patients were used as a training cohort to create a clinical-molecular myelofibrosis transplant scoring system (MTSS), which was then externally validated in a cohort of 156 patients. Read More

View Article

Download full-text PDF

Source
http://www.bloodjournal.org/lookup/doi/10.1182/blood-2018-12
Publisher Site
http://dx.doi.org/10.1182/blood-2018-12-890889DOI Listing
February 2019
1 Read

Stimulated release of intraluminal vesicles from Weibel-Palade bodies.

Blood 2019 Feb 13. Epub 2019 Feb 13.

Molecular and Clinical Sciences Research Institute, St George's University, London, United Kingdom

Weibel-Palade bodies (WPBs) are secretory granules that contain von Willebrand factor and P-selectin, molecules that regulate hemostasis and inflammation respectively. The presence of CD63/LAMP3 in the limiting membrane of WPBs has led to their classification as lysosome-related organelles. Many lysosome-related organelles contain intraluminal vesicles (ILVs) enriched in CD63 that are secreted into the extracellular environment during cell activation to mediate intercellular communication. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2018-09-874552DOI Listing
February 2019
10.452 Impact Factor

Phase 2 study using oral thalidomide-cyclophosphamide-prednisone for idiopathic Multicentric Castleman disease.

Blood 2019 Feb 13. Epub 2019 Feb 13.

Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China;

Idiopathic multicentric Castleman disease (iMCD) is a rare lymphoproliferative disorder. The anti-interleukin(IL)-6 therapy siltuximab is not available everywhere, and is not effective for over half of patients. Alternative treatment approaches are urgently needed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2018-11-884577DOI Listing
February 2019

PHF6 regulates hematopoietic stem and progenitor cells and its loss synergizes with expression of TLX3 to cause leukemia.

Blood 2019 Feb 12. Epub 2019 Feb 12.

The Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia;

Somatically acquired mutations in () frequently occur in hematopoietic malignancies and often coincide with ectopic expression of However, there is yet no functional evidence to demonstrate whether these mutations contribute to tumorigenesis. Similarly, the role of PHF6 in hematopoiesis is unknown. We report here that deletion in mice resulted in a reduced number of hematopoietic stem cells, an increased number of hematopoietic progenitor cells, and an increased proportion of cycling stem and progenitor cells. Read More

View Article

Download full-text PDF

Source
http://www.bloodjournal.org/lookup/doi/10.1182/blood-2018-07
Publisher Site
http://dx.doi.org/10.1182/blood-2018-07-860726DOI Listing
February 2019
1 Read

Peripheral serotonin causes dengue-induced thrombocytopenia through 5HT receptors.

Blood 2019 Feb 12. Epub 2019 Feb 12.

Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore

Dengue virus (DENV) is the most prevalent vector-borne viral pathogen, infecting millions of patients annually. Thrombocytopenia, a reduction in circulating platelet counts, is the most consistent sign of DENV-induced disease, independent of disease severity. However, the mechanisms leading to DENV-induced thrombocytopenia are unknown. Read More

View Article

Download full-text PDF

Source
http://www.bloodjournal.org/lookup/doi/10.1182/blood-2018-08
Publisher Site
http://dx.doi.org/10.1182/blood-2018-08-869156DOI Listing
February 2019
1 Read

The BRISC de-ubiquitinating enzyme complex limits hematopoietic stem cell expansion by regulating JAK2 K63-ubiquitination.

Blood 2019 Feb 12. Epub 2019 Feb 12.

Division of Hematology, Children's Hospital of Philadelphia, Philadelphia, PA, United States;

Hematopoietic stem cell (HSC) homeostasis is controlled by cytokine receptor-mediated JAK2 signaling. We previously found that JAK2 is promptly ubiquitinated upon cytokine stimulation. Whether a competing JAK2 de-ubiquitination activity exists is unknown. Read More

View Article

Download full-text PDF

Source
http://www.bloodjournal.org/lookup/doi/10.1182/blood-2018-10
Publisher Site
http://dx.doi.org/10.1182/blood-2018-10-877563DOI Listing
February 2019
1 Read

Altered NFE2 activity predisposes to leukemic transformation and myelosarcoma with AML-specific aberrations.

Blood 2019 Feb 12. Epub 2019 Feb 12.

Division of Molecular Hematology, University Medical Center Freiburg, Faculty of Medicine, Freiburg, Germany;

In acute myeloid leukemia (AML), acquired genetic aberrations carry prognostic implications and guide therapeutic decisions. Clinical algorithms have been improved by the incorporation of novel aberrations. Here, we report the presence and functional characterization of mutations in the transcription factor NFE2 in AML patients and in a patient with myelosarcoma. Read More

View Article

Download full-text PDF

Source
http://www.bloodjournal.org/lookup/doi/10.1182/blood-2018-09
Publisher Site
http://dx.doi.org/10.1182/blood-2018-09-875047DOI Listing
February 2019
5 Reads

Myelofibrosis osteoclasts are clonal and functionally impaired.

Blood 2019 Feb 11. Epub 2019 Feb 11.

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, United States;

Bone marrow (BM) sclerosis is commonly found in patients with late stage myelofibrosis (MF). Because osteoclasts (OC) and osteoblasts play a key role in bone remodeling, and MF monocytes, the OC precursors, are derived from the neoplastic clone, we wondered whether decreased OC numbers or impairment in their osteolytic function affects the development of osteosclerosis. Analysis of BM biopsies from 50 MF patients showed increased numbers of multinucleated tartrate-resistant acid phosphatase (TRAP)/cathepsin K-positive OC expressing phosphorylated Janus kinase (JAK)-2. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2018-10-878926DOI Listing
February 2019

Anti-CD117 antibody depletes normal and myelodysplastic syndrome human hematopoietic stem cells in xenografted mice.

Blood 2019 Feb 11. Epub 2019 Feb 11.

Department of Pediatrics, Division of Stem Cell Transplantation and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA, United States

The myelodysplastic syndromes (MDS) represent a group of clonal disorders that result in ineffective hematopoiesis and are associated with an increased risk of transformation into acute leukemia. MDS arises from hematopoietic stem cells (HSCs); therefore, successful elimination of MDS HSCs is an important part of any curative therapy. However, current treatment options, including allogeneic hematopoietic cell transplantation (HCT), often fail to ablate disease-initiating MDS HSCs, and thus have low curative potential and high relapse rates. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2018-06-858159DOI Listing
February 2019
1 Read

Ubiquitin-activating enzyme inhibition induces an unfolded protein response and overcomes drug resistance in myeloma.

Blood 2019 Feb 8. Epub 2019 Feb 8.

Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, United States;

Three proteasome inhibitors have garnered regulatory approvals in various multiple myeloma settings but drug resistance is an emerging challenge, and this has prompted interest in blocking upstream components of the ubiquitin-proteasome pathway. One such attractive target is the E1 ubiquitin activating enzyme (UAE), and we therefore evaluated the activity of TAK-243, a novel and specific UAE inhibitor. TAK-243 potently suppressed myeloma cell line growth, induced apoptosis, and activated caspases while decreasing the abundance of ubiquitin-protein conjugates. Read More

View Article

Download full-text PDF

Source
http://www.bloodjournal.org/lookup/doi/10.1182/blood-2018-06
Publisher Site
http://dx.doi.org/10.1182/blood-2018-06-859686DOI Listing
February 2019
1 Read

Relapse of multiple myeloma presenting as pericardial effusion.

Blood 2019 Feb;133(6):619

Centre Hospitalier Universitaire Lille.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2018-11-884221DOI Listing
February 2019
1 Read

Marrow involvement by metastatic spindle cell angiosarcoma.

Blood 2019 Feb;133(6):618

Tuen Mun Hospital.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2018-10-876359DOI Listing
February 2019

Challenging the concept of immunothrombosis.

Blood 2019 Feb;133(6):508-509

Universitätsmedizin Greifswald.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2018-11-886267DOI Listing
February 2019

Roman warfare: targeting of support cells in AML.

Blood 2019 Feb;133(6):506-507

University of California San Francisco.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2018-12-887497DOI Listing
February 2019

Functional profiling to improve therapy in TCL.

Blood 2019 Feb;133(6):504-506

University of Pennsylvania.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2018-12-889741DOI Listing
February 2019

Ravulizumab: a complementary option for PNH.

Authors:
Nathan T Connell

Blood 2019 Feb;133(6):503-504

Harvard Medical School.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2018-12-891499DOI Listing
February 2019

Single-cell technology meets hematology: introduction to a review series.

Blood 2019 Feb 6. Epub 2019 Feb 6.

Chief, Genetics and Molecular Biology Branch, National Institute for Human Genome Research, Bethesda, MD, United States

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2019-01-887224DOI Listing
February 2019

Posttranscriptional modulation of TERC by PAPD5 inhibition rescues hematopoietic development in dyskeratosis congenita.

Blood 2019 Feb 6. Epub 2019 Feb 6.

Center of Regenerative Medicine, Washington University in St. Louis, St. Louis, MO, United States

Reduced levels of , the telomerase RNA component, cause dyskeratosis congenita (DC) in patients harboring mutations in TERC, PARN, NOP10, NHP2, NAF1, or DKC1. Inhibition of the non-canonical poly(A) polymerase , or the exosome RNA degradation complex, partially restores levels in immortalized DKC1 mutant cells, but it remains unknown if modulation of posttranscriptional processing of could improve hematopoietic output in dyskeratosis congenita. We used human embryonic stem cells (hESCs) with a common dyskerin mutation (DKC1_A353V), which have defective telomere maintenance and reduced definitive hematopoietic potential, to understand the effects of reducing EXOSC3 activity, or silencing PAPD5-mediated oligoadenylation, on hematopoietic progenitor specification and function in DC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2018-11-885368DOI Listing
February 2019

Single-cell approaches reveal novel cellular pathways for megakaryocyte and erythroid differentiation.

Blood 2019 Feb 6. Epub 2019 Feb 6.

NIHR Biomedical Research Centre, University of Oxford, Oxford, United Kingdom

The classical model of hematopoiesis proposes a hierarchy in which a small number of multipotent hematopoietic stem cells (HSC) maintain all blood lineages by giving rise to progeny that pass through discrete progenitor stages. At each stage, lineage differentiation potential is restricted, coupled with loss of ability to self-renew. Recently, single cell approaches have been used to test certain assumptions made by this model, in particular relating to megakaryocyte (Mk) and erythroid (E) development. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2018-11-835371DOI Listing
February 2019

New Insights into Haematopoietic Differentiation Landscapes from scRNA-seq.

Blood 2019 Feb 6. Epub 2019 Feb 6.

Department of Haematology, Wellcome & MRC Cambridge Stem Cell Institute, Cambridge, United Kingdom

Single cell transcriptomics has recently emerged as a powerful tool to analyse cellular heterogeneity, discover new cell types and infer putative differentiation routes. The technique has been rapidly embraced by the haematopoiesis research community and like other technologies before, single cell molecular profiling is widely expected to make important contributions to our understanding of the haematopoietic hierarchy. Much of this new interpretation relies on inference of the 'transcriptomic landscape' as a representation of existing cellular states and associated transitions between them. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2018-08-835355DOI Listing
February 2019

Clonal approaches to understanding the impact of mutations on hematologic disease development.

Blood 2019 Feb 6. Epub 2019 Feb 6.

Department of Haematology, University of Cambridge, Cambridge, United Kingdom

Interrogation of hematopoietic tissue at the clonal level has a rich history spanning over 50 years, and has provided critical insights into both normal and malignant hematopoiesis. Characterization of chromosomes identified some of the first genetic links to cancer with the discovery of chromosomal translocations in association with many hematological neoplasms. The unique accessibility of hematopoietic tissue and the ability to clonally expand hematopoietic progenitors in vitro has provided fundamental insights into the cellular hierarchy of normal hematopoiesis, as well as the functional impact of driver mutations in disease. Read More

View Article

Download full-text PDF

Source
http://www.bloodjournal.org/lookup/doi/10.1182/blood-2018-11
Publisher Site
http://dx.doi.org/10.1182/blood-2018-11-835405DOI Listing
February 2019
3 Reads

Dissecting CLL through high dimensional single cell technologies.

Blood 2019 Feb 6. Epub 2019 Feb 6.

Broad Institute of MIT and Harvard, Cambridge, MA, United States

We now have the potential to undertake detailed analysis of the inner workings of thousands of cancer cells, one cell at a time, through the emergence of a range of techniques probing the genome, transcriptome and proteome, combined with the development of bioinformatics pipelines that enable their interpretation. This provides an unprecedented opportunity to better understand the heterogeneity of the disease and how mutations, activation states and protein expression at a single-cell level impact disease course, response to treatment and outcomes. Herein, we review the emerging application of these new techniques to chronic lymphocytic leukemia and examine the fresh insights already attained through this transformative technology. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2018-09-835389DOI Listing
February 2019

Understanding cell fate control by continuous single cell quantification.

Blood 2019 Feb 6. Epub 2019 Feb 6.

Department of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland

Cells and the molecular processes underlying their behavior are highly dynamic. Understanding these dynamic biological processes requires non-invasive, continuous quantitative single-cell observations, instead of population based average or single-cell snap-shot analysis. Ideally, single cell dynamics are measured long-term in vivo. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2018-09-835397DOI Listing
February 2019

Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR-T cells.

Blood 2019 Feb 6. Epub 2019 Feb 6.

Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States.

Autologous T cells engineered to express a CD19-specific chimeric antigen receptor (CAR) have produced impressive minimal residual disease-negative complete remission (MRD-negative CR) rates in patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL). However, the factors associated with durable remissions after CAR-T cells have not been fully elucidated. We studied patients with relapsed/refractory B-ALL enrolled in a phase I/II clinical trial evaluating lymphodepletion chemotherapy followed by CD19 CAR-T cells (NCT01865617, www. Read More

View Article

Download full-text PDF

Source
http://www.bloodjournal.org/lookup/doi/10.1182/blood-2018-11
Publisher Site
http://dx.doi.org/10.1182/blood-2018-11-883710DOI Listing
February 2019
2 Reads
10.452 Impact Factor

Human megakaryocytes possess intrinsic anti-viral immunity through regulated induction of IFITM3.

Blood 2019 Feb 5. Epub 2019 Feb 5.

University of Utah Molecular Medicine Program, Salt Lake City, UT, United States;

Evolving evidence indicates that platelets and megakaryocytes (MKs) have unexpected activities in inflammation and infection; but whether viral infections upregulate biologically active, anti-viral immune genes in platelets and MKs is unknown. We examined anti-viral immune genes in these cells in dengue and influenza infections, viruses that are global public health threats. Using complementary biochemical, pharmacological, and genetic approaches, we examined the regulation and function of interferon induced transmembrane protein 3 (IFITM3), an anti-viral immune effector gene not previously studied in human platelets and MKs. Read More

View Article

Download full-text PDF

Source
http://www.bloodjournal.org/lookup/doi/10.1182/blood-2018-09
Publisher Site
http://dx.doi.org/10.1182/blood-2018-09-873984DOI Listing
February 2019
3 Reads

Dominant activating RAC2 mutation with lymphopenia, immunodeficiency and cytoskeletal defects.

Blood 2019 Feb 5. Epub 2019 Feb 5.

Immunopathogenesis Section, LCIM, NIAID, National Institutes of Health, Bethesda, MD, United States.

RAC2, through interactions with NADPH component p67 , activates neutrophil superoxide production, while interactions with p21-activated kinase (PAK1) are necessary for fMLF-induced actin remodeling. We identified three patients with de novo RAC2[E62K] mutations resulting in severe T- and B-cell lymphopenia, myeloid dysfunction and recurrent respiratory infections. Neutrophils from RAC2[E62K] patients exhibited excessive superoxide production, impaired fMLF-directed chemotaxis, and abnormal macropinocytosis. Read More

View Article

Download full-text PDF

Source
http://www.bloodjournal.org/lookup/doi/10.1182/blood-2018-11
Publisher Site
http://dx.doi.org/10.1182/blood-2018-11-886028DOI Listing
February 2019
8 Reads

Serum levels of TARC, MDC, IL10 and soluble CD163 in Hodgkin lymphoma: a SWOG S0816 correlative study.

Blood 2019 Feb 5. Epub 2019 Feb 5.

James P. Wilmot Cancer Center, University of Rochester, Rochester, NY, United States.

Serum soluble chemokines/cytokines produced by Hodgkin-cells and the tumor microenvironment might be of value as biomarkers in classic Hodgkin lymphoma (cHL). We assessed serum TARC, MDC, IL10, and soluble CD163 (sCD163) levels at baseline, time of interim fluorodeoxyglucose positron emission tomography (FDG-PET), and post-therapy in cHL patients treated on S0816, an intergroup phase 2 response-adapted study evaluating escalated therapy for interim PET(PET2)-positive patients (ClinicalTrials.gov Identifier: NCT00822120). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2018-08-870915DOI Listing
February 2019

CXCL1 regulates neutrophil homeostasis in pneumonia-derived sepsis caused by serotype 3.

Blood 2019 Feb 5. Epub 2019 Feb 5.

Department of Pathobiological Sciences and Center for Experimental Infectious Disease Research, School of Veterinary Medicine, Louisiana State University (LSU), Baton Rouge, LA, United States

Neutrophil migration to the site of bacterial infection is a critical step in host defense. Exclusively produced in the bone marrow, neutrophil release into the blood is tightly controlled. Although the chemokine CXCL1 induces neutrophil influx during bacterial infections, its role in regulating neutrophil recruitment, granulopoiesis, and neutrophil mobilization in response to lung infection-induced sepsis is unclear. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2018-10-878082DOI Listing
February 2019
1 Read

Clinical responses and persistent BRAF+ blood cells in children with LCH treated with MAPK pathway inhibition.

Blood 2019 Feb 4. Epub 2019 Feb 4.

Division of Pediatric Hematology-Oncology, Department of Pediatrics, Baylor College of Medicine, Houston, TX, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2018-10-878363DOI Listing
February 2019

Vitamin D receptor-mediated skewed differentiation of macrophages initiates myelofibrosis and subsequent osteosclerosis.

Blood 2019 Feb 4. Epub 2019 Feb 4.

Hematology, Department of Medicine, Kobe University Graduate School of Medicine, Kobe, Japan;

Myelofibrosis in myeloproliferative neoplasms (MPNs) with mutations such as JAK2V617F is an unfavorable sign for uncontrollable disease progression in the clinic and is complicated with osteosclerosis whose pathogenesis is largely unknown. Because several studies have revealed that macrophages are indispensable supporter for bone forming osteoblasts, we speculated that macrophages might play a significant role in the proliferation of collagen-producing myofibroblasts in marrow fibrotic tissues. Here, we show that myelofibrosis critically depends on macrophages whose differentiation is skewed by vitamin D receptor (VDR) signaling. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2018-09-876615DOI Listing
February 2019
2 Reads

Unusual presentation of classic Hodgkin lymphoma.

Blood 2019 Jan;133(5):502

University of Texas MD Anderson Cancer Center.

View Article

Download full-text PDF

Source
http://www.bloodjournal.org/lookup/doi/10.1182/blood-2018-10
Publisher Site
http://dx.doi.org/10.1182/blood-2018-10-878058DOI Listing
January 2019
6 Reads

Highs and lows of minimal residual disease in CLL.

Blood 2019 Jan;133(5):386-388

University of Utah.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2018-12-889113DOI Listing
January 2019

Contact system sends defensins to the rescue.

Blood 2019 Jan;133(5):385-386

Oregon Health & Science University.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2018-12-887547DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6356987PMC
January 2019

Editing aberrant splice sites efficiently restores β-globin expression in β-thalassemia.

Blood 2019 Jan 31. Epub 2019 Jan 31.

Division of Hematology/Oncology, Boston Children's Hospital, Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Stem Cell Institute, Broad Institute, Boston, MA, United States;

The thalassemias are compelling targets for therapeutic genome editing in part because monoallelic correction of a subset of hematopoietic stem cells (HSCs) would be sufficient for enduring disease amelioration. A primary challenge is the development of efficient repair strategies that are effective in HSCs. Here we demonstrate that allelic disruption of aberrant splice sites, one of the major classes of thalassemia mutations, is a robust approach to restore gene function. Read More

View Article

Download full-text PDF

Source
http://www.bloodjournal.org/lookup/doi/10.1182/blood-2019-01
Publisher Site
http://dx.doi.org/10.1182/blood-2019-01-895094DOI Listing
January 2019
2 Reads
10.452 Impact Factor

How I treat early relapsing follicular lymphoma.

Blood 2019 Jan 30. Epub 2019 Jan 30.

Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, United States.

Follicular lymphoma (FL) is the most frequently occurring indolent non-Hodgkin lymphoma with generally favorable outcomes, but a variable clinical course. Recent studies have elucidated the consistent and reproducible frequency of early disease progression in FL, occurring in approximately 20% of patients. Relapse of FL within 24 months of chemoimmunotherapy (POD24) is now established as a robust marker of poor survival, leading to increased risk of death. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2018-08-822148DOI Listing
January 2019
1 Read

MHC class II cell-autonomously regulates self-renewal and differentiation of normal and malignant B cells.

Blood 2019 Jan 30. Epub 2019 Jan 30.

Department of Medicine, Faculty of Medicine, Imperial College London, London, United Kingdom

Best known for presenting antigenic peptides to CD4+ T cells, major histocompatibility complex class II (MHC II) also transmits or may modify intracellular signals. Here, we show that MHC II cell-autonomously regulates the balance between self-renewal and differentiation in B cell precursors, as well as in malignant B cells. Initiation of MHC II expression early during bone marrow B cell development limited the occupancy of cycling compartments by promoting differentiation, thus regulating the numerical output of B cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2018-11-885467DOI Listing
January 2019
1 Read